C-Path Selects Experienced Neuroscientist to Lead Alzheimer’s Consortium TUCSON, Ariz., March 12, 2020 — The Critical Path Institute (C-Path) today announced it has named Sudhir Sivakumar
February 24, 2020 Use of Biomarkers to Improve Immunosuppressive Drug Development and Outcomes in Renal Organ Transplantation: A Meeting Report
ERA4TB, an International Consortium to Accelerate the Development of Comprehensive Treatments Against Tuberculosis C-Path, Ltd. and more than 30 partners from 13 countries participate in the ERA4TB project. The ERA4TB (European Regimen Ac
December 5, 2019 Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson’s Disease to Inform Clinical Trial Designs Ahamadi M, Conrado DJ, Macha S, Sinha V, Stone J, Burton J, Nicholas T, Gallagher J, Dexter D, Bani M, Boroojerdi B, Smit...
Workshop Summary, Advancing the Development and Implementation of Analysis Data Standards, Now Available C-Path is proud to announce the availability of the workshop summary, Advancing the Development and Implementation of Analysis Dat
U.S. Senator Martha McSally Visits C-Path U.S. Senator Martha McSally (Arizona) visited Tucson-based Critical Path Institute (C-Path) Friday, October 25, to learn more abou
October 22, 2019 Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data
October 21, 2019 Towards EMA Qualification of Islet Auto-Antibodies as a Model-Based Clinical Trial Enrichment Platform for Type-1 Diabetes Prevention Studies